These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 19724688)
1. Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax. Jiang CC; Wroblewski D; Yang F; Hersey P; Zhang XD Neoplasia; 2009 Sep; 11(9):945-55. PubMed ID: 19724688 [TBL] [Abstract][Full Text] [Related]
2. Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Jiang CC; Lucas K; Avery-Kiejda KA; Wade M; deBock CE; Thorne RF; Allen J; Hersey P; Zhang XD Cancer Res; 2008 Aug; 68(16):6708-17. PubMed ID: 18701495 [TBL] [Abstract][Full Text] [Related]
3. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249 [TBL] [Abstract][Full Text] [Related]
4. Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction in myeloma cells couple ER stress to mitochondrial apoptosis. Gomez-Bougie P; Halliez M; Moreau P; Pellat-Deceunynck C; Amiot M Cancer Lett; 2016 Dec; 383(2):204-211. PubMed ID: 27697610 [TBL] [Abstract][Full Text] [Related]
5. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Nguyen M; Marcellus RC; Roulston A; Watson M; Serfass L; Murthy Madiraju SR; Goulet D; Viallet J; Bélec L; Billot X; Acoca S; Purisima E; Wiegmans A; Cluse L; Johnstone RW; Beauparlant P; Shore GC Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19512-7. PubMed ID: 18040043 [TBL] [Abstract][Full Text] [Related]
6. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Huang S; Okumura K; Sinicrope FA Clin Cancer Res; 2009 Jan; 15(1):150-9. PubMed ID: 19118042 [TBL] [Abstract][Full Text] [Related]
7. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo. Dasmahapatra G; Lembersky D; Son MP; Patel H; Peterson D; Attkisson E; Fisher RI; Friedberg JW; Dent P; Grant S Mol Cancer Ther; 2012 May; 11(5):1122-32. PubMed ID: 22411899 [TBL] [Abstract][Full Text] [Related]
8. Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways. Zhang L; Lopez H; George NM; Liu X; Pang X; Luo X Cell Death Differ; 2011 May; 18(5):864-73. PubMed ID: 21113147 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo. Mitchell C; Yacoub A; Hossein H; Martin AP; Bareford MD; Eulitt P; Yang C; Nephew KP; Dent P Cancer Biol Ther; 2010 Nov; 10(9):903-17. PubMed ID: 20855960 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S Blood; 2012 Jun; 119(25):6089-98. PubMed ID: 22446485 [TBL] [Abstract][Full Text] [Related]
11. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835 [TBL] [Abstract][Full Text] [Related]
12. OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis. Wroblewski D; Jiang CC; Croft A; Farrelly ML; Zhang XD; Hersey P PLoS One; 2013; 8(12):e84073. PubMed ID: 24367627 [TBL] [Abstract][Full Text] [Related]
13. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1. Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Konopleva M; Watt J; Contractor R; Tsao T; Harris D; Estrov Z; Bornmann W; Kantarjian H; Viallet J; Samudio I; Andreeff M Cancer Res; 2008 May; 68(9):3413-20. PubMed ID: 18451169 [TBL] [Abstract][Full Text] [Related]
15. Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt. Jiang CC; Yang F; Thorne RF; Zhu BK; Hersey P; Zhang XD Neoplasia; 2009 May; 11(5):436-47. PubMed ID: 19412428 [TBL] [Abstract][Full Text] [Related]
16. Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis. Martínez-Paniagua MA; Baritaki S; Huerta-Yepez S; Ortiz-Navarrete VF; González-Bonilla C; Bonavida B; Vega MI Cell Cycle; 2011 Aug; 10(16):2792-805. PubMed ID: 21822052 [TBL] [Abstract][Full Text] [Related]
17. Disruption of the VDAC2-Bak interaction by Bcl-x(S) mediates efficient induction of apoptosis in melanoma cells. Plötz M; Gillissen B; Hossini AM; Daniel PT; Eberle J Cell Death Differ; 2012 Dec; 19(12):1928-38. PubMed ID: 22705850 [TBL] [Abstract][Full Text] [Related]
18. S1, a novel pan-BH3 mimetic, induces apoptosis in Mcl-1-overexpressing cells through Bak. Song T; Chang X; Zhang Z; Liu Y; Shen X J Pharmacol Sci; 2012; 119(4):330-40. PubMed ID: 22814102 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis. Jiang CC; Chen LH; Gillespie S; Wang YF; Kiejda KA; Zhang XD; Hersey P Cancer Res; 2007 Oct; 67(20):9750-61. PubMed ID: 17942905 [TBL] [Abstract][Full Text] [Related]
20. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Hauck P; Chao BH; Litz J; Krystal GW Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]